| In 000€ | Materialise
Software |
Materialise
Medical |
Materialise
Manufacturing |
Total
segments |
Unallocated
(1) |
Consolidated | ||||||||||||
| For the three months ended December 31, 2021 | ||||||||||||||||||
| Revenues | 12,183 |
|
20,682 |
|
24,135 |
|
57,000 |
|
(11 |
) |
56,989 |
|
||||||
| Segment (adj) EBITDA | 5,518 |
|
6,358 |
|
990 |
|
12,866 |
|
(2,376 |
) |
10,490 |
|
||||||
| Segment (adj) EBITDA % | 45.3 |
% |
30.7 |
% |
4.1 |
% |
22.6 |
% |
18.4 |
% |
||||||||
| For the three months ended December 31, 2020 | ||||||||||||||||||
| Revenues | 10,216 |
|
17,188 |
|
17,889 |
|
45,292 |
|
9 |
|
45,301 |
|
||||||
| Segment (adj) EBITDA | 3,867 |
|
4,844 |
|
1,099 |
|
9,811 |
|
(2,440 |
) |
7,371 |
|
||||||
| Segment (adj) EBITDA % | 37.9 |
% |
28.2 |
% |
6.1 |
% |
21.7 |
% |
16.3 |
% |
||||||||
| In 000€ | Materialise
Software |
Materialise
Medical |
Materialise
Manufacturing |
Total
segments |
Unallocated
(1) |
Consolidated | ||||||||||||
| For the twelve months ended December 31, 2021 | ||||||||||||||||||
| Revenues | 42,902 |
|
73,368 |
|
89,334 |
|
205,604 |
|
(154 |
) |
205,450 |
|
||||||
| Segment (adj) EBITDA | 15,784 |
|
20,669 |
|
6,252 |
|
42,704 |
|
(10,207 |
) |
32,497 |
|
||||||
| Segment (adj) EBITDA % | 36.8 |
% |
28.2 |
% |
7.0 |
% |
20.8 |
% |
15.8 |
% |
||||||||
| For the twelve months ended December 31, 2020 | ||||||||||||||||||
| Revenues | 39,054 |
|
61,729 |
|
69,635 |
|
170,418 |
|
31 |
|
170,449 |
|
||||||
| Segment (adj) EBITDA | 13,383 |
|
13,914 |
|
2,546 |
|
29,843 |
|
(9,465 |
) |
20,378 |
|
||||||
| Segment (adj) EBITDA % | 34.3 |
% |
22.5 |
% |
3.7 |
% |
17.5 |
% |
12.0 |
% |
||||||||
| (1) Unallocated segment adjusted EBITDA consists of corporate research and development, corporate headquarter costs and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA. |
